Treace Medical Concepts announces limited release of Percuplasty™ system for 3D bunion correction, enhancing minimally invasive surgery options.
Quiver AI Summary
Treace Medical Concepts, Inc. has announced the limited market release of its new Percuplasty™ Percutaneous 3D Bunion Correction® System, following successful initial surgical cases. This innovative system aims to enhance bunion surgery with a minimally invasive approach, utilizing small incisions to reduce post-operative pain and facilitate quicker recovery for patients. The Percuplasty™ System is part of Treace's strategy to provide advanced solutions in the metatarsal osteotomy segment, which constitutes a significant portion of the bunion surgical market. CEO John T. Treace expressed excitement about this new offering as a step towards broadening access to effective minimally invasive surgery. Full commercialization is expected in the second half of 2025.
Potential Positives
- The announcement of the limited market release of the Percuplasty™ Percutaneous 3D Bunion Correction® System expands Treace Medical's product line, reinforcing its leadership in 3D bunion correction.
- This new system targets the large metatarsal osteotomy segment, which represents approximately 70% of the annual bunion surgeries in the U.S., providing significant market opportunity.
- The Percuplasty™ System is designed to enhance recovery and cosmetic outcomes for patients, potentially leading to increased demand from both surgeons and patients for minimally invasive surgical options.
- Full commercialization anticipated in the second half of 2025 indicates a structured growth plan and commitment to expanding their market presence significantly in the near future.
Potential Negatives
- The announcement of a "limited market release" may indicate that the product is not fully tested or commercially viable, raising concerns about the product's readiness and market acceptance.
- The anticipated full commercialization of the Percuplasty™ System in the second half of 2025 suggests a prolonged timeline before the product can significantly contribute to revenue, potentially affecting investor sentiment.
- Forward-looking statements highlight inherent risks and uncertainties, which could lead to potential challenges in achieving projected market expansion and revenue growth.
FAQ
What is the Percuplasty™ System?
The Percuplasty™ System is a percutaneous approach for 3D bunion correction, designed to improve recovery and reduce post-operative pain.
When is full commercialization of the Percuplasty™ System planned?
The full commercialization of the Percuplasty™ System is anticipated in the second half of 2025.
How does the Percuplasty™ System differ from previous offerings?
The Percuplasty™ System offers a user-friendly, reproducible approach with low-profile fixation and minimal incisions compared to previous systems.
What surgical needs does Treace Medical Concepts address?
Treace focuses on advancing surgical treatment options for bunions and midfoot deformities, providing comprehensive instrumented solutions for surgeons and patients.
How can I learn more about Treace's products?
More information about Treace's products is available on their website at www.treace.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TMCI Insider Trading Activity
$TMCI insiders have traded $TMCI stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TMCI stock by insiders over the last 6 months:
- JOHN T. TREACE (Chief Executive Officer) has traded it 2 times. They made 2 purchases, buying 135,000 shares and 0 sales.
- JAMES T TREACE purchased 84,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TMCI Hedge Fund Activity
We have seen 63 institutional investors add shares of $TMCI stock to their portfolio, and 67 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,477,707 shares (-62.5%) from their portfolio in Q3 2024
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 1,289,657 shares (-35.0%) from their portfolio in Q3 2024
- GAGNON SECURITIES LLC added 1,286,582 shares (+266.1%) to their portfolio in Q3 2024
- VANGUARD GROUP INC removed 883,406 shares (-24.4%) from their portfolio in Q3 2024
- JPMORGAN CHASE & CO added 861,689 shares (+215.1%) to their portfolio in Q3 2024
- ARMISTICE CAPITAL, LLC added 836,000 shares (+15.6%) to their portfolio in Q3 2024
- GAGNON ADVISORS, LLC added 489,891 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PONTE VEDRA, Fla., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship
Lapiplasty
®
and
Adductoplasty
®
Procedures, today announced the limited market release and first surgical cases utilizing the Percuplasty™ Percutaneous 3D Bunion Correction
®
System and Procedure.
The Percuplasty™ System provides an instrumented, reproducible approach to 3D correction of the bunion deformity through cosmetically appealing, percutaneous incisions designed to minimize post-op pain and swelling, and help patients get back to their active lifestyles quickly. This system represents the Company’s second entry into the metatarsal osteotomy segment--the largest segment of the bunion market--currently estimated to represent approximately 70% of the 450,000 bunion surgeries performed annually in the U.S.
1
“As the pioneers and leaders in 3D Bunion Correction
®
, we are excited to announce the limited market release of Percuplasty™ Percutaneous 3D Bunion Correction System, the second offering in our lineup of instrumented systems designed to democratize 3D minimally invasive osteotomy surgery,” stated John T. Treace, CEO and Founder of Treace. “The Percuplasty™ System follows the limited release of the Nanoplasty™ System, providing an additional, highly differentiated solution in the large metatarsal osteotomy segment of our $5B+ US bunion market opportunity. This represents another significant milestone in our strategy to provide a comprehensive portfolio of instrumented 3D bunion systems to meet the evolving needs of surgeons and patients.”
Oliver N. Schipper MD, of Anderson Orthopaedic Clinic and a member of Treace’s Surgeon Design Team, who performed initial cases with the Percuplasty™ System, commented, “I expect Percuplasty™ will expand surgeon and patient access to the improved recovery and cosmetic benefits of percutaneous bunion surgery through its elegant instrumentation designed to precisely dial in the correction in all three planes and guide the application of fast, low-profile fixation through truly “poke hole” incisions.” Dr. Schipper continued, “For surgeons who are seeking to meet the growing patient demand for MIS bunion surgery without the complexity and steep learning curve traditionally associated with these challenging surgical approaches, the Percuplasty™ System is the new benchmark designed to deliver the user-friendly, reproducible results surgeons have come to expect from Treace.”
Full commercialization of the Percuplasty™ Percutaneous 3D Bunion Correction
®
System is anticipated to occur in the second half of 2025.
More information on Treace’s products can be found at www.treace.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the planned full commercialization of the Company’s Percuplasty™ System in the second half of 2025, and the Company’s expectations regarding expanded surgeon and patient access, growing patient demand for MIS bunion surgery, and that the Company is positioned to significantly increase its share of the overall bunion market and expand its surgeon customer base. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the
“Investor Relations”
section of its website at
www.treace.com
. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty
®
3D Bunion Correction
®
System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty
®
Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty
®
and Adductoplasty
®
procedures, as well as other common bone fusion procedures of the foot. For more information, please visit
www.treace.com
.
To learn more about Treace, connect with us on
LinkedIn
,
X
,
Facebook
and
Instagram
.
iData Research, Inc., 2022.
Dr. Schipper is a paid consultant for the Company.
Contacts:
Treace Medical Concepts, Inc.
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors
:
Gilmartin Group
Vivian Cervantes
IR@treace.net
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
